Cargando…
Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
PURPOSE: The programmed death ligand 1 (PD-L1) SP142 assay with a 1% immune cell (IC) cutoff is approved for the selection of advanced triple-negative breast cancer (TNBC) patients for atezolizumab treatment. We aimed to evaluate the interobserver concordance of PD-L1 scoring and inter-assay variabi...
Autores principales: | Ahn, Soomin, Woo, Ji Won, Kim, Hyojin, Cho, Eun Yoon, Kim, Ahrong, Kim, Jee Yeon, Kim, Chungyeul, Lee, Hee Jin, Lee, Ji Shin, Bae, Young Kyung, Kwon, Youngmee, Kim, Wan Seop, Park, So Yeon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Breast Cancer Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250096/ https://www.ncbi.nlm.nih.gov/pubmed/34128367 http://dx.doi.org/10.4048/jbc.2021.24.e29 |
Ejemplares similares
-
Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips
por: Kim, So-Woon, et al.
Publicado: (2016) -
Genomic profiling of multiple breast cancer reveals inter-lesional heterogeneity
por: Ahn, Soomin, et al.
Publicado: (2020) -
Inter‐pathologist agreement on diagnosis, classification and grading of canine glioma
por: Krane, Gregory A., et al.
Publicado: (2022) -
Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis
por: Turashvili, Gulisa, et al.
Publicado: (2009) -
Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
por: Lee, Seung Eun, et al.
Publicado: (2020)